Client Payment Portal

Employers Should Continue to Use Current I-9 Form Even After Oct. 31 Expiration, DHS Says; ICE Announces I-9 Flexibility Extension

Oct 17, 2022 | Human Resources Services

For more information on the latest I-9 process best practices, consider attending an Oct. 19th WR Immigration webinar: I-9 Updates Webinar Part 2. Register here>>

The Department of Homeland Security (DHS) alerted employers on October 11, 2022, that they should continue using the current Form I-9, Employment Eligibility Verification, even after its October 31, 2022, expiration and “until further notice.” DHS said it will publish a Federal Register notice to announce the new I-9 form when it becomes available.

Also, U.S. Immigration and Customs Enforcement announced an extension until July 31, 2023, of the Form I-9 flexibilities first announced in March 2020. The flexibilities include DHS’s deferral of physical presence requirements applicable to employers and workplaces operating remotely.

Details:

Subscribe to the WR Immigration Newsletters

Start the RFP Process

Join the Corporate Benchmarking Roundtable

Request an Attorney Consultation

Related Posts:

HR’s Crucial Role in Life Sciences IPOs

Much attention has been given to venture investments in New England life sciences companies. Private funding is creating an incredible lift for lab space, office space, hiring, and overall innovation. IPOs, however, deserve as much recognition. Larger and fast-growing companies are heading for the Street, with nearly 50 U.S. biotech...
Read More READ MORE

Avoiding Immigration Pitfalls in Cross-Company Collaboration

Cross-organizational collaboration in the Life Sciences industry is a staple for breakthrough innovation and scaling product distribution.  Working together brings exciting opportunities to address and build new solutions that provide greater impact, reach, and shared profitability. Successful collaboration was perhaps at its strongest during the development of Covid-19 vaccines. The challenges of the pandemic brought together experts from across the pharma industry, government, and academia. The collaborative efforts culminated in the development...
Read More READ MORE